Compare Jemperli vs. Keytruda
Head-to-head comparisons of medication uses, side effects, warnings, and more.
- Jemperli (dostarlimab)Keytruda (pembrolizumab)
- Jemperli (dostarlimab)Keytruda (pembrolizumab)
Summary of Jemperli vs. Keytruda
Summary for PD-1 inhibitorPrescription onlyJemperli (dostarlimab-gxly or dostarlimab) is FDA approved to treat adults with endometrial cancer, or uterine cancer. This medication can also treat certain types of cancers that have specific abnormalities called dMMR. Jemperli (dostarlimab) is an immunotherapy medication called a PD-1 inhibitor. It’s given as an infusion through the vein every 3 weeks at first and then every 6 weeks. Some side effects include fatigue, nausea, and rash.
Summary for PD-1 inhibitorPrescription onlyKeytruda (pembrolizumab) is an immunotherapy medication that’s used to treat many different types of cancer, including non-small cell lung cancer (NSCLC), breast cancer, and melanoma. This medication turns on your immune system so it can attack cancer cells. It's given as an intravenous (IV) infusion at a medical office or infusion center. Sometimes, Keytruda (pembrolizumab) can cause side effects, like diarrhea, rash, and trouble breathing, that might need to be treated with corticosteroids. Depending on the cancer, your treatment plan can consist of Keytruda (pembrolizumab) by itself or with other anticancer therapy.
Indications of Jemperli vs. Keytruda
Indications for•Advanced or recurrent endometrial cancer, including those that are mismatch repair deficient (dMMR)•Advanced or recurrent dMMR solid tumors, when previous treatment no longer works and no other alternative options are availableIndications forCertain types of:
•Non-small cell lung cancer (NSCLC)•Renal cell carcinoma (kidney cancer)•Endometrial carcinoma (uterine cancer)•Cancers with high tumor mutation burden (TMB-H), high microsatellite instability (MSI-H), or deficient mismatch repair (dMMR)Pros and Cons of Jemperli vs. Keytruda
Pros and Const for PD-1 inhibitorPros•Only need an infusion every 3 or 6 weeks•Infusion time is relatively short (takes about 30 minutes)•Helps your own immune system work better to fight the cancerCons•Given as an infusion through the vein (IV)•Commonly causes fatigue•Can cause immune-related side effects, such as rash, which might require additional treatmentPros and Const for PD-1 inhibitorPros•Recommended first-choice treatment for many types of cancers under certain situations•Less likely to cause nausea, vomiting, and hair loss (side effects that are common with traditional chemotherapy)•Given every 3 or 6 weeks, depending on the treatment plan•Uses your own immune system to attack cancer cellsCons•Given as an injection through the veins•Might cause immune-related side effects like diarrhea, rash, and lung problems•Though rare, can cause infusion reactions•Might require you to take a break from treatment and take a corticosteroid to manage side effectsCommon Side Effects of Jemperli vs. Keytruda
Common Side Effects for•Fatigue or feeling very tired (49%)•Low white blood cell count (up to 46%)•Anemia (low red blood cell count; 35%)•Higher creatinine levels (33%)•Nausea (32%)•Elevated liver enzyme levels (up to 31%)•Diarrhea (29%)•Constipation (23%)•Vomiting (23%)•Rash (21%)Common Side Effects for•Higher blood sugar (52%)•Anemia (43%)•Higher liver enzyme levels (up to 33%)•Electrolyte changes in blood (up to 31%)•Lower white blood cells (30%)•Tiredness (25%)•Lower appetite (17%)•Trouble breathing (17%)•Cough (16%)•Rash (15%)•Diarrhea (12%)•Constipation (12%)•Nausea (12%)Warnings of Jemperli vs. Keytruda
Common Side Effects for•Immune-related side effects•Infusion-related reactions•Complications from stem cell transplants•Harm to an unborn babyCommon Side Effects for•Immune-related side effects•Infusion-related reactions•Complications from stem cell transplants•Harm to unborn babyPrices with our coupons for Jemperli vs. Keytruda
Compare other Uterine Cancer drugs
Browse medications
View AllResearch prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.